Limit of annual procedures in British Columbia for Duodopa therapy removed

We are pleased to share the BC Pharmacare announcement that Duodopa is now listed on formulary effective Dec. 10, 2020, which means there will no longer be a cap on the number of BC Duodopa patients per year. The BC criteria for access to Duodopa is now similar to other provinces.

Treatments like this are a primary focus of our upcoming webinar, Progressing Parkinson’s Disease – A discussion on Device Aided Therapies. You can register to attend this webinar, which takes place on Dec. 14, 2020.

From a press release by the Parkinson Society British Columbia:

British Columbia’s Ministry of Health has announced today that they have removed the yearly limit on the number of British Columbians who can receive Duodopa® therapy. Previously, BC PharmaCare only covered five individuals per year for this therapy, resulting in a two-year waitlist for Parkinson’s patients experiencing debilitating symptoms.

Duodopa® is used to treat patients with advanced Parkinson’s disease who have severe and disabling motor symptoms that cannot be well controlled with available combinations of medications. It is a levodopa and carbidopa drug combination delivered in the form of a gel through an intestinal pump.

Read the full press release here.

Leave a Reply

Your email address will not be published. Required fields are marked *